Ascites in Pediatrics

(Outline followed by detailed chapter)

I. Definition

Ascites is the pathologic accumulation of fluid in the peritoneal cavity, typically due to liver dysfunction, portal hypertension, or systemic disease. It is a hallmark of hepatic decompensation and often the first clinical sign of worsening liver disease in children.

II. Pathogenesis

III. Etiology

A. Cirrhotic Causes

B. Noncirrhotic Causes

IV. Diagnosis

V. Management

A. Sodium Restriction

B. Diuretics

C. Fluid Restriction

D. Albumin Infusion

E. Paracentesis

F. Spontaneous Bacterial Peritonitis (SBP)

G. Surgical Options

VI. Complications

VII. References




Ascites in Pediatric Liver Disease

Comprehensive Review

Introduction

Ascites—defined as the pathologic accumulation of fluid within the peritoneal cavity—serves as one of the first overt signs of decompensated liver disease in children. While adult patients develop ascites almost exclusively from cirrhosis and portal hypertension, the pediatric differential is broader, encompassing congenital, infectious, inflammatory, metabolic, and neoplastic disorders. A deep understanding of the forces driving fluid formation, the spectrum of underlying diseases, and a methodical diagnostic and therapeutic approach are essential for clinicians and trainees specializing in pediatric hepatology.

Pathophysiology

Under normal conditions, fluid filters from the splanchnic capillaries into the interstitial and peritoneal spaces and is returned by lymphatic drainage. Ascites forms when the balance of Starling forces—that is, hydrostatic and oncotic pressures across capillary membranes—is disrupted or when lymphatic drainage capacity is overwhelmed.

In cirrhosis, fibrotic remodeling of the liver parenchyma increases resistance to portal blood flow, producing portal hypertension. The elevated hydrostatic pressure within the splanchnic vasculature forces plasma water into the peritoneal cavity. Concurrently, endothelial nitric oxide synthase activity increases, causing splanchnic vasodilation. As systemic arterial pressure falls, baroreceptors trigger activation of the renin–angiotensin–aldosterone system (RAAS), the sympathetic nervous system, and antidiuretic hormone (ADH) release. Aldosterone enhances sodium reabsorption in the distal nephron, while ADH promotes free water retention in the collecting ducts. The net effect is expansion of the extracellular fluid volume, with a preferential shift of fluid into the peritoneal compartment.

Portal hypertension also accelerates lymph formation in the hepatic and mesenteric beds. When lymphatic capacity is exceeded, the excess protein-rich fluid leaks directly into the peritoneal cavity. Hypoalbuminemia—common in chronic liver disease—further lowers plasma oncotic pressure, augmenting fluid extravasation into the peritoneal space.

Etiology

Cirrhotic Causes

In children, cirrhosis may arise from a range of genetic, cholestatic, and metabolic disorders. Biliary atresia results from obliteration of the extrahepatic bile ducts, leading to chronic cholestasis and progressive periportal fibrosis. In autoimmune hepatitis, immune-mediated destruction of hepatocytes and bile ducts produces interface hepatitis and bridging fibrosis. Storage diseases such as Wilson disease and alpha-1 antitrypsin deficiency deposit toxic substances within hepatocytes, provoking inflammation and fibrogenesis. Congenital hepatic fibrosis reflects ductal plate malformation and periportal fibrosis present from birth. Regardless of the underlying trigger, these conditions converge on portal hypertension, sinusoidal leak, and the salt-retaining neurohormonal responses that drive ascites formation.

Noncirrhotic and Extrahepatic Causes

A variety of noncirrhotic processes can produce ascites in children. Infectious agents such as Tuberculosis, cytomegalovirus, or Epstein–Barr virus can inflame the peritoneum or hepatic sinusoids, yielding exudative or mixed transudative ascitic fluid. Primary intestinal diseases—from Crohn disease to meconium ileus—may cause local peritoneal inflammation or mechanical leaks. Acute pancreatitis and pseudocyst rupture introduce enzyme-rich fluid into the peritoneum. Systemic lupus erythematosus and Henoch–Schönlein purpura can provoke serositis with peritoneal effusion.

Cardiovascular disorders such as congestive heart failure or constrictive pericarditis raise central venous pressure, favoring transudation of fluid into the abdominal cavity. Renal diseases like nephrotic syndrome lower plasma oncotic pressure, similarly promoting fluid extravasation. Genitourinary abnormalities—posterior urethral valves or bladder rupture—may allow urine to leak into the peritoneal space. Chylous ascites results from lymphatic disruption (for example, thoracic duct injury), flooding the abdomen with lipid-rich lymph. Neoplastic processes—including neuroblastoma, Wilms tumor, lymphoma, or germ cell tumors—can seed the peritoneum or obstruct lymphatics. Finally, iatrogenic factors such as ventriculoperitoneal shunts may leak cerebrospinal fluid, presenting as ascites.

Clinical Presentation

In infants and young children, ascites often becomes apparent as progressive abdominal distension, feeding difficulties, and respiratory distress from diaphragmatic elevation. Physical examination may reveal shifting dullness or a detectable fluid wave, although small or loculated pockets of fluid can be missed without imaging. Older children with chronic liver disease may report a sense of fullness or early satiety and display peripheral edema. Associated stigmata of chronic liver disease—jaundice, spider angiomas, palmar erythema, and splenomegaly—support a diagnosis of cirrhosis. A rapid onset of ascites in a previously healthy child should prompt evaluation for infection, vascular thrombosis, pancreatic leak, or other acute processes.

Diagnostic Evaluation

A systematic approach distinguishes portal-hypertensive from non–portal-hypertensive ascites, guides therapy, and identifies treatable causes. Initial laboratory studies assess hepatic synthetic function (AST, ALT, bilirubin, albumin), coagulation status (PT/INR), and renal performance (BUN, creatinine). Urinalysis and measurement of urinary sodium excretion provide insight into neurohormonal activation and diuretic responsiveness.

Imaging—primarily ultrasound with Doppler interrogation—confirms ascitic fluid, estimates its volume, characterizes liver echotexture, and evaluates flow in the portal and hepatic veins. Cross-sectional imaging (CT or MRI) is reserved for suspected mass lesions or vascular anomalies.

When the etiology is unclear or infection is suspected, diagnostic paracentesis is imperative. Ascitic fluid should be analyzed for total and differential cell counts, albumin and total protein concentrations, glucose, lactate dehydrogenase (LDH), bilirubin, amylase, triglycerides, microbiology (culture and acid-fast smear), and cytology if malignancy is in the differential.

The serum-ascites albumin gradient (SAAG)—calculated as the difference between the simultaneous serum and ascitic fluid albumin concentrations—serves as a robust discriminator. A SAAG ≥1.1 g/dL indicates portal hypertension (typical in cirrhosis, congenital hepatic fibrosis, or cardiac causes), whereas a SAAG <1.1 g/dL suggests exudative processes such as infection, malignancy, or pancreatic leaks.

Key Components of Ascitic Fluid Analysis
Parameter Clinical Significance
Polymorphonuclear leukocyte count PMN > 250/mm³ confirms spontaneous bacterial peritonitis (SBP)
Albumin Required for SAAG calculation
Total protein Helps distinguish exudate from transudate
Glucose Low in infection; elevated in pancreatic ascites
LDH Indicator of cellular injury
Bilirubin High in bile leaks
Amylase Signature of pancreatic origin
Triglycerides Elevated in chylous ascites
Microbiology & Cytology Identifies pathogens or malignant cells

When noninvasive testing fails to establish a diagnosis, liver biopsy—performed percutaneously or via a transjugular route in coagulopathic patients—provides histopathologic insights into fibrosis, inflammation, or vascular obstruction.

Management

Treatment of pediatric ascites revolves around alleviating symptoms, preventing complications, and addressing the underlying etiology. Dietary sodium restriction—targeting 1–2 mEq/kg/day in young children and 1–2 g/day in adolescents—reduces the renal sodium pool available for retention. Breastfed infants typically require no restriction due to the naturally low sodium content of human milk, whereas formula-fed infants may benefit from specialized low-sodium preparations. Fluid restriction is reserved for severe hyponatremia (serum Na⁺ < 125 mEq/L) and aims to balance intravascular volume without precipitating prerenal azotemia.

Pharmacologic diuresis employs spironolactone to antagonize aldosterone at the distal nephron and furosemide to inhibit sodium and chloride reabsorption in the thick ascending limb of Henle’s loop. Monitoring includes daily weight measurements and spot urine Na⁺/K⁺ ratios, with a ratio above 1 indicating effective natriuresis.

Diuretic Therapy for Pediatric Ascites
Diuretic Mechanism of Action Infant Dose Child Dose Maximum Daily Dose
Spironolactone Aldosterone receptor antagonist at the distal nephron 0.5–1 mg/kg/day 1–3 mg/kg/day 100 mg/day
Furosemide Inhibits Na⁺/Cl⁻ reabsorption in Henle’s loop 0.5–2 mg/kg/day 0.5–2 mg/kg/day 40 mg/day

In cases refractory to diuretics, large-volume paracentesis safely evacuates fluid, relieving respiratory compromise and discomfort. When serum albumin falls below 2.5 g/dL, infusion of 5 % or 25 % albumin at 0.5–1 g/kg may restore oncotic pressure and support intravascular volume; pairing albumin with furosemide can mitigate post-paracentesis circulatory dysfunction.

Spontaneous bacterial peritonitis (SBP)—diagnosed by an ascitic PMN count above 250 cells/mm³—carries high morbidity and mortality. Empiric therapy with a third-generation cephalosporin (e.g., cefotaxime) or a broad-spectrum β-lactam/β-lactamase inhibitor combination (e.g., piperacillin-tazobactam) should be initiated promptly, with subsequent tailoring based on culture results.

For refractory portal-hypertensive ascites, transjugular intrahepatic portosystemic shunt (TIPS) creation decompresses the portal system, reducing hydrostatic pressure and ascitic accumulation. Peritoneovenous shunts are rarely used in pediatrics due to high rates of thrombosis and infection. Ultimately, liver transplantation remains the definitive therapy for children with end-stage liver disease and recurrent or refractory ascites.

Complications

Beyond discomfort and respiratory compromise, ascites predisposes children to a spectrum of life-threatening complications. SBP can precipitate sepsis, renal failure, and hepatic encephalopathy. Large-volume fluid shifts increase the risk of hepatorenal syndrome through intense renal vasoconstriction. Malnutrition, variceal hemorrhage, and impaired growth compound the clinical burden, underscoring the necessity of vigilant monitoring and timely intervention.

Conclusion

Ascites in pediatric liver disease represents the culmination of intricate hemodynamic, hormonal, and lymphatic derangements. While portal hypertension and cirrhosis remain cornerstone mechanisms, the broad pediatric differential demands a thorough evaluation for noncirrhotic etiologies. A structured diagnostic strategy—leveraging laboratory studies, imaging, paracentesis with SAAG calculation, and histology—guides targeted therapy. Management centers on sodium and fluid control, judicious diuresis, infection prevention, and consideration of TIPS or transplantation. Mastery of these concepts empowers clinicians to intervene early, mitigate complications, and optimize outcomes for children afflicted with ascites.


References

American Association for the Study of Liver Diseases. (2021). Diagnosis, evaluation, and management of ascites and spontaneous bacterial peritonitis in cirrhosis: Practice guidance. Hepatology, 74(3), 1012–1032.

Giefer, M. J., Murray, K. F., & Colletti, R. B. (2011). Pathophysiology, diagnosis, and management of pediatric ascites. Journal of Pediatric Gastroenterology and Nutrition, 52(5), 503–513.

Ginès, P., Cárdenas, A., Arroyo, V., & Schrier, R. W. (2004). Management of cirrhosis and ascites. New England Journal of Medicine, 350(16), 1646–1654.

Kramer, R. E., Sokol, R. J., Yerushalmi, B., Colletti, R. B., & Abramson, M. (2001). Large‐volume paracentesis in the management of ascites in children. Journal of Pediatric Gastroenterology and Nutrition, 33(3), 245–249.

Runyon, B. A., Montano, A. A., Akriviadis, E. A., Antillon, M., Irving, M. F., & McHutchison, J. G. (1992). The serum–ascites albumin gradient is superior to the exudate–transudate concept in the differential diagnosis of ascites. Annals of Internal Medicine, 117(3), 215–220.

Sabri, M., Saps, M., & Peters, J. M. (2003). Pathophysiology and management of pediatric ascites. Current Gastroenterology Reports, 5(3), 240–246.